$1.85
0.073.93%
At close: -
$1.60
-0.25-13.51%
After Hours: 4:08 AM EDT
Comments
Loading...
Camp4 Therapeutics Analyst Ratings and Price Targets | NASDAQ:CAMP | Benzinga
Camp4 Therapeutics Corp has a consensus price target of $9.4 based on the ratings of 8 analysts. The high is $23 issued by JP Morgan on November 5, 2024. The low is $0.3 issued by Goldman Sachs on January 11, 2024. The 3 most-recent analyst ratings were released by Leerink Partners, JP Morgan, and Piper Sandler on November 5, 2024, respectively. With an average price target of $19.33 between Leerink Partners, JP Morgan, and Piper Sandler, there's an implied 1108.33% upside for Camp4 Therapeutics Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Leerink Partners
JP Morgan
Piper Sandler
Goldman Sachs
Craig-Hallum
1calculated from analyst ratings
Analyst Ratings for Camp4 Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/05/2024 | Buy Now | — | William Blair | Myles Minter40% | — | Initiates | → Outperform | Get Alert |
| 11/05/2024 | Buy Now | 962.5% | Leerink Partners | Mani Foroohar48% | → $17 | Initiates | → Outperform | Get Alert |
| 11/05/2024 | Buy Now | 1337.5% | JP Morgan | Eric Joseph43% | → $23 | Initiates | → Overweight | Get Alert |
| 11/05/2024 | Buy Now | 1025% | Piper Sandler | Edward Tenthoff51% | → $18 | Initiates | → Overweight | Get Alert |
| 01/11/2024 | Buy Now | -81.25% | Goldman Sachs | Jerry Revich52% | $8.05 → $6.9 | Maintains | Sell | Get Alert |
| 10/09/2023 | Buy Now | -78.13% | Goldman Sachs | Jerry Revich52% | $18.4 → $8.05 | Maintains | Sell | Get Alert |
| 10/06/2023 | Buy Now | -68.75% | Craig-Hallum | Anthony Stoss54% | → $11.5 | Downgrade | Buy → Hold | Get Alert |
| 10/06/2023 | Buy Now | 212.5% | Roth MKM | Scott Searle69% | $138 → $115 | Maintains | Buy | Get Alert |
| 08/29/2023 | Buy Now | 275% | Roth MKM | Scott Searle69% | → $138 | Reiterates | Buy → Buy | Get Alert |
| 07/13/2023 | Buy Now | -50% | Goldman Sachs | Jerry Revich52% | $63.25 → $18.4 | Maintains | Sell | Get Alert |
| 07/11/2023 | Buy Now | 25% | Craig-Hallum | Anthony Stoss54% | $92 → $46 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 25% | Jefferies | George Notter73% | $115 → $46 | Downgrade | Buy → Hold | Get Alert |
| 05/01/2023 | Buy Now | 71.87% | Goldman Sachs | Jerry Revich52% | $73.6 → $63.25 | Maintains | Sell | Get Alert |
| 04/28/2023 | Buy Now | 150% | Craig-Hallum | Anthony Stoss54% | $230 → $92 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 100% | Goldman Sachs | Jerry Revich52% | $85.1 → $73.6 | Maintains | Sell | Get Alert |
| 10/14/2022 | Buy Now | 131.25% | Goldman Sachs | Jerry Revich52% | $98.9 → $85.1 | Maintains | Sell | Get Alert |
| 08/16/2022 | Buy Now | 525% | Craig-Hallum | Anthony Stoss54% | $184 → $230 | Upgrade | Hold → Buy | Get Alert |
FAQ
What is the target price for Camp4 Therapeutics (CAMP) stock?
The latest price target for Camp4 Therapeutics (NASDAQ:CAMP) was reported by William Blair on November 5, 2024. The analyst firm set a price target for $0.00 expecting CAMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Camp4 Therapeutics (CAMP)?
The latest analyst rating for Camp4 Therapeutics (NASDAQ:CAMP) was provided by William Blair, and Camp4 Therapeutics initiated their outperform rating.
When was the last upgrade for Camp4 Therapeutics (CAMP)?
The last upgrade for Camp4 Therapeutics Corp happened on August 16, 2022 when Craig-Hallum raised their price target to $10. Craig-Hallum previously had a hold for Camp4 Therapeutics Corp.
When was the last downgrade for Camp4 Therapeutics (CAMP)?
The last downgrade for Camp4 Therapeutics Corp happened on October 6, 2023 when Craig-Hallum changed their price target from N/A to $0.5 for Camp4 Therapeutics Corp.
When is the next analyst rating going to be posted or updated for Camp4 Therapeutics (CAMP)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Camp4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Camp4 Therapeutics was filed on November 5, 2024 so you should expect the next rating to be made available sometime around November 5, 2025.
Is the Analyst Rating Camp4 Therapeutics (CAMP) correct?
While ratings are subjective and will change, the latest Camp4 Therapeutics (CAMP) rating was a initiated with a price target of $0.00 to $0.00. The current price Camp4 Therapeutics (CAMP) is trading at is $1.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.